What is occupying the foreground.

At Proteinea

Making the science of Fc engineering legible: to our team, to partners, and eventually to the people whose lives depend on better medicines.

Between Cairo and the US

I’m thinking about what a globally ambitious company can be when it is not culturally or geographically singular. The answer is still being built, in flights and in long conversations.

A draft question

Why does pharma become more open, more biological, and more accountable to the immune systems it hopes to change?

Draft language — a question I’m testing, not a claim.